These innovative molecules represent a significant advancement in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://oisiykwr503845.kylieblog.com/39700271/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide